Epidermal growth factor receptor (EGFR) has been heavily exploited as a target for blockade in cancer therapy. In normal epithelial cells, ligand-induced internalization of activated receptors and their sorting for degradation in lysosomes is the limiting mechanism for EGFR signaling. This desensitization process is commonly circumvented by cancer cells to promote their growth and survival even in the presence of EGFR signaling inhibitors. We have identified a novel role for the sterol biosynthesis pathway to influence this recycling process which could significantly improve the efficacy of EGFR-targeting inhibitors. Silencing of SC4MOL (sterol C4-methyl oxidase-like) significantly sensitizes tumor cells to EGFR inhibitors using a network-guided siRNA-based screen (Astsaturov, 2010). We have determined that SC4MOL and a functionally linked partner protein, NSDHL (NADP-dependent steroid dehydrogenase-like), are negative regulators of trafficking of EGFR and its family members ErbB2 and ErbB3 from the plasma membrane to the lysosome for destruction. Our central hypothesis is that metabolic blockade of the sterol biosynthesis pathway will accelerate receptor degradation and thus suppress EGFR signaling in vitro;in NSDHL conditional knockout mice, this will limit epithelial carcinogenesis. Our immediate objective is to validate a new metabolic target for cancer therapy involving these previously unexplored genes in the distal sterol biosynthesis pathway. With the strong team of collaborators assembled, we propose the following 3 specific Aims:
Aim 1. Investigate the mechanism of EGFR signaling regulation by genes in the sterol biosynthesis pathway. On the basis of preliminary data and complementary bioinformatics analysis, we hypothesize that blockade of SC4MOL and NSDHL causes altered EGFR trafficking that accelerates EGFR degradation in lysosomes.
Aim 2. Determine the value of combined targeting of SC4MOL and EGFR in tumor xenografts. Based on our preliminary in vitro data, we propose that shRNA silencing of SC4MOL will increase the response of tumor xenografts to EGFR blockade.
Aim 3. Investigate in vivo effects of sterol pathway on EGFR signaling and susceptibility to carcinogens. We hypothesize that the EGFR-antagonistic effects of the epithelial NSDHL deficiency will limit the H-Ras-dependent or -independent carcinogenesis. This proposal is significant because it will provide fundamentally new knowledge on how the metabolism of sterols regulates signaling activity of essential cancer receptors such as EGFR. We believe that pharmacological inhibition of sterol pathway targets such as SC4MOL and NSDHL has the potential for cancer chemotherapy and chemoprevention as an entirely novel class of agents.

Public Health Relevance

The NCI Transition Career Development Award (K22) submitted by Igor Astsaturov, M.D., Ph.D. proposes to study a novel cancer-relevant target in the sterol metabolic pathway regulating EGFR signaling. The project titled """"""""Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy"""""""" will provide fundamentally new knowledge on how the blockade of sterol metabolism can suppress activity and accelerate degradation of essential cancer receptors such as EGFR. We believe that pharmacological inhibition of sterol pathway targets, SC4MOl and associated NSDHL, has the potential to provide the basis for cancer chemotherapy and chemoprevention with an entirely novel class of agents. The written critiques and criteria scores of individual reviewers are provided in essentially unedited form in the """"""""Critique"""""""" section below. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The """"""""Resume and Summary of Discussion"""""""" section above summarizes the final opinions of the committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Career Transition Award (K22)
Project #
1K22CA160725-01
Application #
8165559
Study Section
Subcommittee G - Education (NCI)
Program Officer
Jakowlew, Sonia B
Project Start
2011-07-01
Project End
2014-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$199,245
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Bobrov, Egor; Skobeleva, Natalia; Restifo, Diana et al. (2017) Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget 8:4399-4409
Gerson, James N; Skariah, Sam; Denlinger, Crystal S et al. (2017) Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 26:531-540
Beglyarova, Natalya; Banina, Eugenia; Zhou, Yan et al. (2016) Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res 22:6153-6163
Gabitova, Linara; Restifo, Diana; Gorin, Andrey et al. (2015) Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR. Cell Rep 12:1927-38
Gabitova, Linara; Gorin, Andrey; Astsaturov, Igor (2014) Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20:28-34
Perkins, James; Boland, Patrick; Cohen, Steven J et al. (2014) Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study. J Natl Compr Canc Netw 12:847-52
Beeharry, Neil; Banina, Eugenia; Hittle, James et al. (2014) Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle 13:2172-91
Nikonova, Anna S; Astsaturov, Igor; Serebriiskii, Ilya G et al. (2013) Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 70:661-87
Bagnyukova, T V; Restifo, D; Beeharry, N et al. (2013) DUSP6 regulates drug sensitivity by modulating DNA damage response. Br J Cancer 109:1063-71
Mehra, Ranee; Serebriiskii, Ilya G; Burtness, Barbara et al. (2013) Aurora kinases in head and neck cancer. Lancet Oncol 14:e425-35

Showing the most recent 10 out of 12 publications